Health
Emyria and partner Mind Medicine Australia launch psychedelic-assisted therapy program targeting PTSD – Proactive Investors Australia
EMDMA-001 has been modelled on a major Phase III clinical trial developed by the Multidisciplinary Association for Psychedelic Studies (MAPS).
EMDMA-001 has been modelled on a major Phase III clinical trial developed by the Multidisciplinary Association for Psychedelic Studies (MAPS). Emyria Ltd (ASX:EMD) and partner Mind Medicine Australia have launched the EMDMA-001 psychedelic-assisted therapy program targeting sufferers of treatment-resistant post-traumatic stress disorder (PTSD).
As a first step, and pending ethics approval, Emyria, an innovative drug development and clinical services company, will sponsor a major, independently monitored,…
-
Noosa News22 hours agoRallies under way as nationwide support for Palestine surges
-
General24 hours agoNRL live updates: Newcastle Knights vs Brisbane Broncos, Wests Tigers vs North Queensland Cowboys — blog, scores and stats
-
General19 hours agoThousands flood cities demanding action on Palestine
-
Noosa News22 hours agoHusband charged after beloved Brisbane nurse Carra Luke allegedly stabbed to death in Taigum home